エヌトレクチニブ
エヌトレクチニブ 物理性質
- 沸点 :
- 717.5±60.0 °C(Predicted)
- 比重(密度) :
- 1.340±0.06 g/cm3(Predicted)
- 貯蔵温度 :
- Store at -20°C
- 溶解性:
- ≥28.05 mg/mL in DMSO; insoluble in H2O; ≥9.82 mg/mL in EtOH with ultrasonic
- 外見 :
- solid
- 酸解離定数(Pka):
- 12.01±0.43(Predicted)
- InChIKey:
- HAYYBYPASCDWEQ-UHFFFAOYSA-N
- SMILES:
- C(NC1C2=C(NN=1)C=CC(CC1=CC(F)=CC(F)=C1)=C2)(=O)C1=CC=C(N2CCN(C)CC2)C=C1NC1CCOCC1
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
エヌトレクチニブ 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
エヌトレクチニブ 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬
説明
Entrectinib (RXDX-101, Ignyta Pharmaceuticals, San Diego, CA, USA) is a small
molecule that inhibits the tyrosine kinases TRKA/B/C, ROS1, and ALK (Table?1). It
has a preclinical median inhibitory concentration (IC50) of 7?nm against ROS1, higher
than crizotinib [95, 96]. Entrectinib was specifically designed to cross the blood-brain
barrier [95].
使用
Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity. RXDX-101 has demonstrated potent pharmacological activity in preclinical studies and has the potential to be first-in-class against the Trk family of kinases. PXDX-101 has been well tolerated in patients with advanced solid tumors. PXDX-101 is currently in clinical trials, and is being developed by Ignyta.
臨床応用
Entrectinib demonstrated potent antitumor effects in tumor cell lines and patient-derived xenograft (PDX) tumor models in preclinical studies. Furthermore, entrectinib can cross the blood–brain barrier (BBB) to impact primary brain tumors and brain metastases in patients with NTRK1/ NTRK2/NTRK3, ROS1, and ALK fusion-driven cancers.
エヌトレクチニブ 上流と下流の製品情報
原材料
Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)(2,2,2-trifluoroacetyl)amino]-
Benzamide, 2-?amino-?N-?[5-?[(3,?5-?difluorophenyl)?methyl]?-?1H-?indazol-?3-?yl]?-?4-?(4-?methyl-?1-?piperazinyl)?-
3,5-ジフルオロベンジル ブロミド
5-(3,5-difluorobenzyl)-2-fluorobenzonitrile
4-フルオロ-2-ニトロ安息香酸
tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate
4-Fluoro-2-Nitro-Benzoic Acid Tert-Butyl Ester
tert-butyl 2-amino-4-(4-methylpiperazin-1-yl)benzoate
3-アミノ-5-(3,5-ジフルオロベンジル)-1H-インダゾール
4-(4-methylpiperazin-1-yl)-2-[(tetrahydropyran-4-yl)(2,2,2-trifluoroacetyl)amino]benzoic acid tert-butyl ester
4-(4-methylpiperazin-1-yl)-2-[(tetrahydropyran-4-yl)amino]benzoic acid tert-butyl ester
4-(4-methylpiperazin-1-yl)-2-[(tetrahydropyran-4-yl)(2,2,2-trifluoroacetyl)amino]benzoic acid trifluoroacetate
3-シアノ-4-フルオロフェニルボロン酸
テトラヒドロ-4H-ピラン-4-オン
準備製品
エヌトレクチニブ 生産企業
Global( 196)Suppliers
エヌトレクチニブ スペクトルデータ(1HNMR、MS)
1108743-60-7(エヌトレクチニブ)キーワード:
- 1108743-60-7
- Entrectinib
- Entrectinib(NMS-E628)
- N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide
- RXDX-101
- Entrectinib,NMS-E628,RXDX-101
- entrecitinib
- Entrectinib(RXDX-101)
- NMS-E628
- CS-1589
- NMS E628; RXDX-101;NMSE628; RXDX 101;NMS-E628; RXDX101
- RXDX101; RXDX 101; RXDX-101; NMS E628; NMSE628; NMS-E628; ENTRECTINIB
- Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-
- ROZLYTREK)
- N-[5-[(3,5-Difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]benzamide
- 13C,2H3]-Entrectinib
- Biopterin Impurity 4
- エヌトレクチニブ
- エントレクチニブ
- エヌトレクチニブ (JAN)
- N-[5-(3,5-ジフルオロベンジル)-1H-インダゾール-3-イル]-2-[(テトラヒドロ-2H-ピラン-4-イル)アミノ]-4-(4-メチルピペラジノ)ベンズアミド
- N-{5-[(3,5-ジフルオロフェニル)メチル]-1H-インダゾール-3-イル}-4-(4-メチルピペラジン-1-イル)-2-[(オキサン-4-イル)アミノ]ベンズアミド
- N-[5-(3,5-ジフルオロベンジル)-1H-インダゾール-3-イル]-2-(テトラヒドロ-2H-ピラン-4-イルアミノ)-4-(4-メチルピペラジン-1-イル)ベンズアミド